Embolization

Global Embolotherapy Market Outlook, 2019-2024 - Embolic Agents to Register a Significant Growth Rate Owing to New Product Approvals

Retrieved on: 
Wednesday, August 14, 2019
Interventional radiology, Embolization

This report studies the embolotherapy market based on product, disease indication, procedure, end user, and region.

Key Points: 
  • This report studies the embolotherapy market based on product, disease indication, procedure, end user, and region.
  • Based on product, the embolotherapy market is broadly segmented into embolic agents and support devices.
  • The embolic agent's segment is further sub-segmented into embolic coils, embolic plug systems, liquid embolic agents, microspheres, and detachable balloons.
  • The embolic agents segment is anticipated to register the highest growth over the forecast period owing to new product approvals and launches in the segment.

$1.5 Billion Interventional Oncology Market by Procedure, Product, Application, and End User - Global Forecast to 2025

Retrieved on: 
Friday, August 16, 2019
Medicine, Medical specialties, Health, Interventional radiology, Cancer, Interventional oncology, Radiology, Surgical oncology, Radiofrequency ablation, Oncology, Embolization, Ablation

DUBLIN, Aug. 16, 2019 /PRNewswire/ -- The "Interventional Oncology Market by Procedure [Embolization (TARE, TACE), Ablation (Thermal Ablation (Microwave, RF Ablation))], Product, Application (Liver, Lung, Breast), and End User - Global Forecast to 2025" report has been added to ResearchAndMarkets.com's offering.

Key Points: 
  • DUBLIN, Aug. 16, 2019 /PRNewswire/ -- The "Interventional Oncology Market by Procedure [Embolization (TARE, TACE), Ablation (Thermal Ablation (Microwave, RF Ablation))], Product, Application (Liver, Lung, Breast), and End User - Global Forecast to 2025" report has been added to ResearchAndMarkets.com's offering.
  • The global interventional oncology market is estimated to grow at a CAGR of 7.7% from 2019 to reach $1,506.3 million by 2025.
  • The study also evaluates industry competitors and analyzes the market at regional and country level.
  • The interventional oncology market for hospitals (end-user segment) is estimated to command the largest share of the global market in 2019.

Global Neurovascular Devices Market Review 2013-2019 & Forecast to 2024

Retrieved on: 
Thursday, August 1, 2019
Medical specialties, Medicine, Stryker Corporation, Vascular diseases, Health care, Boston Scientific, Embolization, Aneurysm

Dublin, Aug. 01, 2019 (GLOBE NEWSWIRE) -- The "Neurovascular Devices Market Analysis By Device Type, By Therapeutic Applications And Segment Forecasts, 2013 - 2024" report has been added to ResearchAndMarkets.com's offering.

Key Points: 
  • Dublin, Aug. 01, 2019 (GLOBE NEWSWIRE) -- The "Neurovascular Devices Market Analysis By Device Type, By Therapeutic Applications And Segment Forecasts, 2013 - 2024" report has been added to ResearchAndMarkets.com's offering.
  • The global neurovascular device market was valued at USD 1.62 billion in the year 2015 and is expected to reach a value of USD 2.92 billion by 2024, growing at a CAGR of 6.5%.
  • Moreover, Stryker Corporation is a key leader in the neurovascular device market, owing to the strategic acquisition of complete neurovascular portfolio of Boston Scientific Corporation in the year 2010.
  • On the basis of types, the market is segmented into embolization and aneurysms coils, stenting systems, neurothrombectomy and support devices.

Global Neurovascular Devices Market Poised to Witness a CAGR of 6.5%, Reaching $2.92 Billion by 2024 - ResearchAndMarkets.com

Retrieved on: 
Thursday, August 1, 2019
Medical devices, Health, Medical specialties, Medicine, Interventional radiology, Vascular diseases, Embolization, Surgery, Aneurysm

The "Neurovascular Devices Market Analysis By Device Type, By Therapeutic Applications And Segment Forecasts, 2013 - 2024" report has been added to ResearchAndMarkets.com's offering.

Key Points: 
  • The "Neurovascular Devices Market Analysis By Device Type, By Therapeutic Applications And Segment Forecasts, 2013 - 2024" report has been added to ResearchAndMarkets.com's offering.
  • The global neurovascular device market was valued at USD 1.62 billion in the year 2015 and is expected to reach a value of USD 2.92 billion by 2024, growing at a CAGR of 6.5%.
  • The market is segmented on the basis of device type and respective therapeutic applications.
  • On the basis of types, the market is segmented into embolization and aneurysms coils, stenting systems, neurothrombectomy and support devices.

Global Aneurysm Coiling and Embolization Devices to 2026: Growing Frequency of Unruptured Intracranial Aneurysm (UlAs) Detection and Technological Developments

Retrieved on: 
Friday, July 26, 2019
Medical specialties, Medicine, Neurosurgery, Angiology, Interventional radiology, Vascular diseases, Cerebrovascular diseases, Aneurysm, Gross pathology, Intracranial aneurysm, Embolization, Internal carotid artery

DUBLIN, July 26, 2019 /PRNewswire/ -- The "Aneurysm Coiling and Embolization Devices - Global Market Outlook (2017-2026)" report has been added to ResearchAndMarkets.com's offering.

Key Points: 
  • DUBLIN, July 26, 2019 /PRNewswire/ -- The "Aneurysm Coiling and Embolization Devices - Global Market Outlook (2017-2026)" report has been added to ResearchAndMarkets.com's offering.
  • Some of the key factors influencing the market growth include the growing frequency of unruptured intracranial aneurysm (UlAs) detection and technological developments.
  • The Aneurysm Coiling & Embolization Devices are the Embolization Device (PED) is specified for the endovascular action of adults with huge wide-necked intracranial aneurysms (lAs) in the internal carotid vein from the petrous to the big hypophyseal sections.
  • The increased healthcare expenditure and the strong presence of established vendors are significant factors for the high growth of the aneurysm coiling and embolization devices market in this region.

Aneurysm Coiling and Embolization Devices - Global Market Outlook 2017-2026 - ResearchAndMarkets.com

Retrieved on: 
Friday, July 26, 2019
Health, Medical devices, Cardiology, Medical specialties, Medicine, Neurosurgery, Angiology, Interventional radiology, Vascular diseases, Cerebrovascular diseases, Aneurysm, Gross pathology, Intracranial aneurysm, Embolization, Internal carotid artery

The "Aneurysm Coiling and Embolization Devices - Global Market Outlook (2017-2026)" report has been added to ResearchAndMarkets.com's offering.

Key Points: 
  • The "Aneurysm Coiling and Embolization Devices - Global Market Outlook (2017-2026)" report has been added to ResearchAndMarkets.com's offering.
  • Some of the key factors influencing the market growth include the growing frequency of unruptured intracranial aneurysm (UlAs) detection and technological developments.
  • The Aneurysm Coiling & Embolization Devices are the Embolization Device (PED) is specified for the endovascular action of adults with huge wide-necked intracranial aneurysms (lAs) in the internal carotid vein from the petrous to the big hypophyseal sections.
  • The increased healthcare expenditure and the strong presence of established vendors are significant factors for the high growth of the aneurysm coiling and embolization devices market in this region.

Recommendations for Personalised HCC Treatment With Y90 TheraSphere™ Published by an International Multidisciplinary Group

Retrieved on: 
Tuesday, July 23, 2019
Medicine, Medical specialties, Radiation therapy, Clinical medicine, Medical physics, Radiobiology, TheraSphere, Hepatology, Interventional radiology, Hepatocellular carcinoma, Embolization, Dosimetry

LONDON, July 23, 2019 /PRNewswire/ -- BTG plc (LSE: BTG), a global healthcare company, today announced consensus recommendations for personalised treatment for hepatocellular carcinoma (HCC) with TheraSphere have been published by an international multidisciplinary working group1.

Key Points: 
  • LONDON, July 23, 2019 /PRNewswire/ -- BTG plc (LSE: BTG), a global healthcare company, today announced consensus recommendations for personalised treatment for hepatocellular carcinoma (HCC) with TheraSphere have been published by an international multidisciplinary working group1.
  • Higher response rates of 71% were seen in the personalised prospective dosimetry arm vs 36% with standard dosimetry.
  • "The working group reached a consensus recommendation on simple, reproducible and evidence-based practice for personalised treatment of HCC patients with TheraSphere.
  • We provide high value patient-centric treatment options which include locally-applied embolisation, radiotherapy with Y90 glass microspheres and cryoablation.

Recommendations for Personalised HCC Treatment With Y90 TheraSphere™ Published by an International Multidisciplinary Group

Retrieved on: 
Tuesday, July 23, 2019
Medicine, Medical specialties, Branches of biology, Medical physics, Radiobiology, Radiation protection, TheraSphere, Interventional radiology, Radiation therapy, Dosimetry, Embolization, Cryoablation

Higher response rates of 71% were seen in the personalised prospective dosimetry arm vs 36% with standard dosimetry.

Key Points: 
  • Higher response rates of 71% were seen in the personalised prospective dosimetry arm vs 36% with standard dosimetry.
  • "The working group reached a consensus recommendation on simple, reproducible and evidence-based practice for personalised treatment of HCC patients with TheraSphere.
  • For each scenario, recommendations are provided on patient selection, treatment planning and dosimetry, treatment delivery and outcome assessment and degree of recommendation and the strength of consensus.
  • We provide high value patient-centric treatment options which include locally-applied embolisation, radiotherapy with Y90 glass microspheres and cryoablation.

The Global Embolization Coil Market is Forecast to Grow by up to 5%, 2019-2023 - ResearchAndMarkets.com

Retrieved on: 
Friday, July 12, 2019
Medical devices, Health, Interventional radiology, Embolization, Surgery

Analysts have predicted that the embolization coil market will register a CAGR of almost 5% by 2023.

Key Points: 
  • Analysts have predicted that the embolization coil market will register a CAGR of almost 5% by 2023.
  • Many governments are promoting the usage of the embolization coil through state-led initiatives and regulatory approval support by introducing favorable reimbursement policies.
  • Nowadays, even developing economies such as China and India are also introducing reimbursement policies for the embolization coil.
  • Complications with embolization coils occur due to migration of coil, misplacement of coils, incomplete retrieval of the coil, coil stretching, limited coil length range, and non-target embolization.

Midwest Institute for Non-Surgical Therapy Opens Unique Fibroid Center: Innovative Treatment of Large Fibroids Without Surgery

Retrieved on: 
Thursday, July 11, 2019
Medicine, Medical specialties, Clinical medicine, Interventional radiology, Gynaecological neoplasia, RTT, Uterine fibroid, Uterine artery embolization, Hysterectomy, UFE, Fibroid, Embolization

The Fibroid Center also offers one-to-one nursing and a high-success rate of treating large fibroids without the need for costly and painful surgeries.

Key Points: 
  • The Fibroid Center also offers one-to-one nursing and a high-success rate of treating large fibroids without the need for costly and painful surgeries.
  • Fibroids are usually diagnosed by a specialist via an MRI and can be subdivided into multiple types depending on their location.
  • The Fibroid Center at MINT is St. Louis's first and only comprehensive center dedicated to the non-surgical treatment of Uterine Fibroids.
  • Specializing in uterine fibroid embolization (UFE), the Fibroid Center at MINT allows fibroid sufferers to seek relief from the painful reality of uterine fibroids without the need for invasive surgery or a hysterectomy.